Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
14 06 2019
Historique:
received: 17 05 2019
revised: 06 06 2019
accepted: 12 06 2019
entrez: 19 6 2019
pubmed: 19 6 2019
medline: 25 7 2020
Statut: epublish

Résumé

Hepatitis E virus infection is a significant public health problem in many parts of the world including Africa. We tested serum samples from 900 patients in Burkina Faso presenting with febrile icterus. They all tested negative for yellow fever, but those from 23/900 (2.6%) patients contained markers of acute HEV infection (anti-HEV IgM and HEV RNA positive). Genotyping indicated that 14 of the strains were HEV genotype 2b. There was an overall HEV IgG seroprevalence of 18.2% (164/900). In a bivariate analysis, the factors linked to HEV exposure were climate and patient age. Older patients and those living in arid regions were more likely to have HEV infection. HEV genotype 2b circulating only in humans can be involved in some acute febrile icterus cases in Burkina Faso. Better access to safe water, sanitation, and improved personal hygiene should improve control of HEV infection in this country.

Identifiants

pubmed: 31207982
pii: v11060554
doi: 10.3390/v11060554
pmc: PMC6630816
pii:
doi:

Substances chimiques

Hepatitis Antibodies 0
Immunoglobulin G 0
Immunoglobulin M 0
RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

The authors declare no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Références

J Clin Microbiol. 2012 Mar;50(3):897-902
pubmed: 22205792
Transfusion. 2017 Jan;57(1):223-224
pubmed: 28097700
J Gen Virol. 2016 Mar;97(3):537-542
pubmed: 26743685
MMWR Morb Mortal Wkly Rep. 2015 May 22;64(19):537
pubmed: 25996097
Virol J. 2018 Oct 23;15(1):163
pubmed: 30352598
Emerg Infect Dis. 2010 Jan;16(1):126-9
pubmed: 20031058
Cold Spring Harb Perspect Med. 2019 Jun 3;9(6):
pubmed: 29735579
Clin Infect Dis. 2010 Aug 1;51(3):328-34
pubmed: 20572761
J Infect Dev Ctries. 2016 Jan 31;10(1):24-9
pubmed: 26829534
Emerg Infect Dis. 2008 Apr;14(4):681-3
pubmed: 18394300
Viruses. 2016 Aug 05;8(8):
pubmed: 27527210
J Gen Virol. 2004 Jan;85(Pt 1):89-95
pubmed: 14718623
J Clin Microbiol. 2017 May;55(5):1299-1312
pubmed: 28202798
J Clin Virol. 2018 Aug;105:109-111
pubmed: 29957544
AIDS. 2013 Jan 28;27(3):487-9
pubmed: 23291543
PLoS One. 2012;7(10):e48125
pubmed: 23110187
Am J Trop Med Hyg. 2018 Oct;99(4):1055-1057
pubmed: 30062983
J Gen Virol. 2000 Apr;81(Pt 4):903-9
pubmed: 10725415
Nat Rev Dis Primers. 2017 Nov 16;3:17086
pubmed: 29154369
Clin Microbiol Infect. 2012 Oct;18(10):982-8
pubmed: 22264267
Am J Trop Med Hyg. 2017 Jun;96(6):1296-1301
pubmed: 28719276
Am J Trop Med Hyg. 2013 Feb;88(2):329-38
pubmed: 23208879
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29530950
Emerg Infect Dis. 2016 Apr;22(4):755-7
pubmed: 26982195
J Med Virol. 2005 Dec;77(4):519-21
pubmed: 16254969
J Clin Virol. 2009 Oct;46(2):140-4
pubmed: 19651539
J Med Virol. 1996 Oct;50(2):117-9
pubmed: 8915876
Clin Infect Dis. 2010 Apr 1;50(7):1006-10
pubmed: 20178415
J Biomed Sci. 2000 Jul-Aug;7(4):334-8
pubmed: 10895057
Virol J. 2008 Dec 22;5:158
pubmed: 19102767
BMC Infect Dis. 2014 Jun 05;14:308
pubmed: 24902967
Am J Trop Med Hyg. 2015 Dec;93(6):1356-9
pubmed: 26438027
Gastroenterology. 2016 Feb;150(2):355-7.e3
pubmed: 26551551
Clin Microbiol Rev. 2014 Jan;27(1):116-38
pubmed: 24396139
Emerg Infect Dis. 2009 Jan;15(1):110-4
pubmed: 19116067

Auteurs

Chloé Dimeglio (C)

Laboratoire de virologie, Centre national de référence du virus de l'hépatite E, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France. dimeglio.c@chu-toulouse.fr.

Dramane Kania (D)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. draka3703@yahoo.fr.

Judith Mbombi Mantono (JM)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. mantonochancelvie@yahoo.fr.
Université Catholique d'Afrique de l'Ouest, Bobo-Dioulasso, Burkina Faso. mantonochancelvie@yahoo.fr.

Thérèse Kagoné (T)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. tskagone@gmail.com.

Sylvie Zida (S)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. zida_sylvie@yahoo.fr.
Institut de recherche en sciences de la santé (IRSS), Ouagadougou, Burkina Faso. zida_sylvie@yahoo.fr.

Souleymane Tassembedo (S)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. tassoulee@yahoo.fr.

Amadou Dicko (A)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. dicko22@gmail.com.

Bachirou Tinto (B)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. tintobachirou@yahoo.fr.

Seydou Yaro (S)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. yaro_seydou@yahoo.com.

Hervé Hien (H)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. hien_herve@hotmail.com.

Jérémi Rouamba (J)

Centre MURAZ, Bobo-Dioulasso, Burkina Faso. jeremirouamba@gmail.com.
Université Ouaga I Pr Joseph KI-ZERBO, Ouagadougou, Burkina Faso. jeremirouamba@gmail.com.

Brice Bicaba (B)

Institut de recherche en sciences de la santé (IRSS), Ouagadougou, Burkina Faso. bicaba_brico@yahoo.fr.

Isaïe Medah (I)

Ministère de la Santé, Ouagadougou, Burkina Faso. isaiemedah@yahoo.fr.

Nicolas Meda (N)

Ministère de la Santé, Ouagadougou, Burkina Faso. nicolas.meda@gmail.com.

Oumar Traoré (O)

Agence nationale de biosécurité, Ouagadougou, Burkina Faso. kourouda@gmail.com.

Edouard Tuaillon (E)

Pathogenesis and Control of Chronic Infections., Etablissement Français du Sang, CHU Montpellier, INSERM, University of Montpellier, 34090 Montpellier, France. e-tuaillon@chu-montpellier.fr.

Florence Abravanel (F)

Laboratoire de virologie, Centre national de référence du virus de l'hépatite E, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France. bravanel.f@chu-toulouse.fr.
Centre de Physiopathologie de Toulouse Purpan (CPTP), UMR Inserm, U1043, UMR CNRS, U5282, 31300 Toulouse, France. bravanel.f@chu-toulouse.fr.

Jacques Izopet (J)

Laboratoire de virologie, Centre national de référence du virus de l'hépatite E, CHU Toulouse, Hôpital Purpan, 31300 Toulouse, France. izopet.j@chu-toulouse.fr.
Centre de Physiopathologie de Toulouse Purpan (CPTP), UMR Inserm, U1043, UMR CNRS, U5282, 31300 Toulouse, France. izopet.j@chu-toulouse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH